UK-Based Pharmaceutical Company Selects Cardiocore as Preferred Provider
Cardiocore, a centralized cardiac testing lab, announced that it has been selected as a preferred provider by a UK-based specialty pharmaceutical company.
Leading UK-Based Pharmaceutical Company Selects Cardiocore as Preferred Provider
Core Lab Provides Advanced Methods and Specialized Expertise
Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected as a preferred provider by a top UK-based specialty pharmaceutical company. Before choosing Cardiocore as one of its two preferred providers, this multinational drug developer conducted a four-month selection process comparing the world’s leading core labs. Key selection criteria included scientific expertise, data management capabilities, global service quality and financial stability.
In 2008, this sponsor contracted Cardiocore to provide nearly $2.5 million in cardiac safety services including a Phase III-B global trial, a Phase IV post marketing study and a Thorough QT trial with intravenous dose administration. As part of the Thorough QT data analysis, Cardiocore applied the technically advanced “Holter Bin” methodology to help the sponsor eliminate the potentially misleading effects of subjects’ natural heart rate variability on their QTc interval results.
Cardiocore is delivering ongoing cardiac safety services for this client’s European project teams based in England and their North American project teams based in Pennsylvania. Over the next three years, the sponsor intends to outsource additional cardiac testing projects including Thorough QT and global late stage studies.
Providing value-added support for the customer’s pediatric research programs, Cardiocore has deployed its team of board certified pediatric cardiologists. Since there are vital differences between child and adult ECG interpretation, the specialization of board certified pediatric cardiologists represent best-in-class expertise for clinical studies within childhood populations.
“We are delighted to earn this preferred provider award,” said Cardiocore CEO, Jennifer Cotteleer. She added, “In addition to ECG, Holter and ECHO analyses and global logistical support, Cardiocore is pleased to provide our partner with value-adding scientific consulting and data management services. We look forward to a long and successful relationship.”
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 15 years. Services include centralized electrocardiographic (ECG) analysis, Holter monitoring, echocardiography, statistical analysis and consulting services such as protocol design. The company is experienced in both the design and the implementation of cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s CardioCorrect® system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
